{"prompt": "['2014-0546', 'August 7, 2017', 'Page 4 of 49', 'LIST OF ABBREVIATIONS AND DEFINITION OF TERMS', 'Abbreviation', 'Definition', 'ADL', 'Activities of daily living', 'ADR', 'Adverse drug reaction', 'AE', 'Adverse event', 'AKT', 'Serine-threonine kinase', 'ALT', 'Alanine transaminase', 'AML', 'Acute myeloid leukemia', 'ANC', 'Absolute neutrophil count', 'ASH', 'American Society of Hematology', 'AST', 'Aspartate transaminase', 'AUC0-a', 'Area under the plasma concentration-time curve from 0 to infinity', 'AZA', 'Azacitidine', 'BID', 'Twice daily', 'BM', 'Bone marrow', 'BMBL', 'Bone marrow blast', 'BMCR', 'Bone marrow complete response', 'BUN', 'Blood urea nitrogen', 'C1D1, C2D1', 'Cycle 1 Day 1, Cycle 2 Day 1', 'Cmax', 'Maximum plasma concentration', 'CBC', 'Complete blood count', 'CDC25', 'Cell division cycle 25', 'CDK', 'Cyclin-dependent kinase', 'CFR', 'Code of Federal Regulations', 'CI', 'Clinical improvement', 'CIV', 'Continuous intravenous', 'CRO', 'Contract research organization', 'CSR', 'Clinical study report', 'CT', 'Computed tomography', 'CTCAE', 'Common Terminology Criteria for Adverse Events']['2014-0546', 'August 7, 2017', 'Page 5 of 49', 'Abbreviation', 'Definition', 'CYP', 'Cytochrome P450', 'DLT', 'Dose-limiting toxicity', 'ECG', 'Electrocardiogram', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'Electronic case report form', 'EMH', 'Extramedullar hematopoiesis', 'EOS', 'End of study', 'EPO', 'Erythropoietin', 'ER', 'Erythroid response', 'ERES', 'Electronic Records/Electronic Signatures', 'ERK', 'Extracellular signal-regulated kinase', 'ESA', 'Erythropoiesis-stimulating agent', 'ET', 'Essential thrombocythemia', 'FAS', 'Full analysis set', 'FDA', 'Food & Drug Administration', 'FISH', 'Fluorescent in-situ hybridization', 'GCP', 'Good clinical practice', 'G-CSF', 'Granulocyte colony-stimulating factor', 'GI', 'Gastrointestinal', 'GM-CSF', 'Granulocyte-macrophage colony-stimulating factor', 'Hgb', 'Hemoglobin', 'HIV', 'Human immunodeficiency virus', 'HMA', 'Hypomethylating agent', 'hr', 'Hour', 'IB', \"Investigator's brochure\", 'ICF', 'Informed consent form', 'ICH', 'International Conference on Harmonisation', 'Int-1', 'Intermediate-1', 'IPSS', 'International Prognostic Scoring System']['2014-0546', 'August 7, 2017', 'Page 6 of 49', 'Abbreviation', 'Definition', 'IRAE', 'Immediately Reportable Adverse Event', 'IRB', 'Institutional Review Board', 'IV', 'Intravenous', 'IWG-MRT', 'International Working Group for Myelofibrosis Research and', 'Treatment', 'JAK2', 'Janus kinase 2', 'LCM', 'Left coastal margin', 'LDH', 'Lactate dehydrogenase', 'MAPK', 'Mitogen-activated protein kinase', 'MDS', 'Myelodysplastic syndromes', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MF', 'Myelofibrosis', 'MFSAF', 'Myelofibrosis self assessment form', 'MRI', 'Magnetic resonance imaging', 'MTD', 'Maximum tolerated dose', 'NCI', 'National Cancer Institute', 'NHLBI', 'National Heart Lung and Blood Institute', 'ON 01910.Na', 'rigosertib sodium (rigosertib); sodium salt of (E)-2,4,6-', 'trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl', 'sulfone', 'os', 'Overall survival', 'PB', 'Peripheral blood', 'PD', 'Progressive disease', 'P-gp', 'P-glycoprotein', 'PI3K', 'Phosphatidylinositol-3 kinase', 'PK', 'Pharmacokinetic', 'PLK', 'Polo-like kinase', 'PLT', 'Platelet', 'PMF', 'Primary myelofibrosis']\n\n###\n\n", "completion": "END"}